NDA 209363 · Evofem INC
Solosec
Secnidazole · Oral · Nitroimidazole Antimicrobial
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Sep 15, 2017
Approved uses
4
Original approval plus efficacy supplements
Registered trials
10
5 Phase 3, 1 recruiting
FAERS reports
282
66 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 30, 2026.
SOLOSEC ® is a nitroimidazole antimicrobial indicated for: Treatment of bacterial vaginosis in female patients 12 years of age and older. ( 1.1 ) Treatment of trichomoniasis in patients 12 years of age and older. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) 1.1 Bacterial Vaginosis SOLOSEC is indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older [see Use in Specific Populations (8.1) and Clinical Studies (14) ]. 1.2 Trichomoniasis SOLOSEC is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis in patients 12 years of age and older. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, treat partners of infected patients simultaneously in order to prevent reinfection [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . 1.3 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: SOLOSEC is a nitroimidazole antimicrobial drug [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 26, 2022 Supplement 16 · Efficacy LabelLetter
- Jan 26, 2022 Supplement 14 · Efficacy LabelLetter
- Jun 30, 2021 Supplement 12 · Efficacy LetterLabel
- Sep 15, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- SOLOSEC · SECNIDAZOLE 2GM/PACKET · GRANULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Secnidazole" as an intervention, any sponsor and status, largest first.
- Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and SecnidazolePivotal-lookingRecruiting
Tulane UniversityAcademic, hospital or other
NCT06261840 · 1,200 participants (planned) · Start May 6, 2025 · Primary completion May 1, 2029
Drug: Metronidazole 500 mg; Secnidazole 2000 MG · For: Trichomonas Vaginitis; Bacterial Vaginitis
Sites: Birmingham, Alabama; North Miami, Florida; New Orleans, Louisiana · 4 sites in all
- Studies of Immune Responses to Orally Administered Vaccines in Developing CountryPivotal-lookingCompleted
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT01019083 · 1,016 participants (planned) · Start Feb 2008 · Primary completion Dec 2010
Drug: Placebo; Placebo and 2 more · For: Cholera; Typhoid
Sites: Dhaka, Bangladesh
- Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in BangladeshPivotal-lookingCompleted
University of CambridgeAcademic, hospital or other
NCT00607074 · 410 participants · Start Jun 2003 · Primary completion Apr 2004
Drug: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole); Anti-Giardia treatment only (secnidazole or albendazole) and 1 more · For: Giardiasis
Sites: Mohakhali, Bangladesh
- Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219Pivotal-lookingCompleted
Symbiomix TherapeuticsIndustry
NCT02452866 · 325 participants · Start Jun 2015 · Primary completion Oct 2015
Drug: SYM-1219 · For: Bacterial Vaginosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Jonesboro, Arkansas · 40 sites in all
- A Phase 2 Study of SYM-1219 to Treat Bacterial VaginosisPivotal-lookingCompleted
Symbiomix TherapeuticsIndustry
NCT02147899 · 215 participants · Start May 2014 · Primary completion Oct 2014
Drug: SYM-1219; Placebo · For: Bacterial Vaginosis
Sites: Birmingham, Alabama; San Diego, California; Clearwater, Florida · 16 sites in all
- A Phase 3 Study of Solosec® for the Treatment of TrichomoniasisPivotal-lookingCompleted
Lupin Research IncIndustry
NCT03935217 · 147 participants · Start Apr 23, 2019 · Primary completion Mar 2, 2020
Drug: Secnidazole; Placebo · For: Trichomonas Infection
Sites: Birmingham, Alabama; North Miami, Florida; Chicago, Illinois · 11 sites in all
- Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal DischargePivotal-lookingCompleted
Universidad Nacional de ColombiaAcademic, hospital or other
NCT02111629 · 118 participants · Start May 2012 · Primary completion Feb 2013
Drug: Fluconazole and Secnidazole · For: Vaginal Discharge
Sites: Bogotá D.C, Colombia
Quanta MedicalIndustry
NCT01733966 · 100 participants · Start May 2010 · Primary completion Mar 2012
Drug: Secnidazole, ciprofloxacine; Amoxicillin-Clavulanic Acid · For: Diverticular Sigmoïditis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting78
- nausea51
- drug ineffective31
- diarrhoea23
- wrong technique in product usage process22
- product taste abnormal21
- headache20
- dysgeusia18
- abdominal pain17
- malaise13
- no adverse event13
- abdominal discomfort11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2016 | 1 |
| 2018 | 54 |
| 2019 | 108 |
| 2020 | 64 |
| 2021 | 16 |
| 2022 | 10 |
| 2023 | 11 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Solosec (Secnidazole)
2024 spending
$56K
Beneficiaries
157
190 claims
Per beneficiary
$358
$280.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $121,421 |
| 2021 | $86,936 |
| 2022 | $82,812 |
| 2023 | $70,234 |
| 2024 | $56,144 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Amoebic dysentery.
Marie C, Petri WA · BMJ Clin Evid 2013 · Systematic Review
- Amoebic dysentery.
Mackey-Lawrence NM, Petri WA · BMJ Clin Evid 2011 · Systematic Review
- Amoebic dysentery.
Dans LF, Martínez EG · BMJ Clin Evid 2007 · Systematic Review
- Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.
Mergenhagen KA, Wattengel BA, Skelly MK, et al. · Antimicrob Agents Chemother 2020 · Research Support, U.S. Gov't, Non-P.H.S., Systematic Review
- Secnidazole for treatment of bacterial vaginosis: a systematic review.
Abd El Aziz MA, Sharifipour F, Abedi P, et al. · BMC Womens Health 2019 · Systematic Review
- Efficacy and safety of different drugs for the treatment of bacterial vaginosis: a systematic review and network meta-analysis.
Fan Y, Gu Y, Xian Y, et al. · Front Cell Infect Microbiol 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Evofem INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.